MAP2K7 and colorectal carcinoma: Besides, Combined inhibition of both MEK and CDK4/6 is effective in preclinical models of KRAS mutant CRC (Colorectal Cancer) and justifies a planned phase II clinical trial in patients with refractory KRAS-mutant CRC27.